Trial Profile
Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Mar 2024
Price :
$35
*
At a glance
- Drugs Golimumab (Primary) ; Purines
- Indications Ulcerative colitis
- Focus Adverse reactions
- Acronyms OPAL
- Sponsors Janssen Biotech
- 12 Apr 2023 Planned End Date changed from 30 Jul 2027 to 10 Dec 2026.
- 12 Apr 2023 Planned primary completion date changed from 30 Jul 2027 to 10 Dec 2026.
- 21 Dec 2021 Planned End Date changed from 30 Jul 2031 to 30 Jul 2027.